Comparative Pharmacology
Head-to-head clinical analysis: DISOMER versus LORATADINE REDIDOSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DISOMER versus LORATADINE REDIDOSE.
DISOMER vs LORATADINE REDIDOSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective dopamine D2 receptor antagonist; also blocks alpha-1 adrenergic, histamine H1, and muscarinic M1 receptors.
Selective peripheral H1 receptor antagonist; inhibits histamine release from mast cells.
Adults: 1 mg orally once daily.
10 mg orally once daily
None Documented
None Documented
12–15 hours in adults with normal renal function; prolonged to 30–40 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is 8–14 hours (mean ~12 hours) for desloratadine (active metabolite); parent loratadine half-life ~3–20 hours (mean ~8 hours). Clinically, once-daily dosing maintains steady state in 5–7 days.
Renal: 80% as unchanged drug; biliary/fecal: 15% as metabolites; <5% unchanged in feces.
Renal (approximately 40% as metabolites), biliary/fecal (approximately 60% as metabolites). Less than 1% excreted unchanged in urine.
Category C
Category A/B
Antihistamine
Antihistamine